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Lymphatic metastasis is facilitated by lymphangiogenic growth factor vascular
endothelial growth factor‐C (VEGFC) that is secreted by some primary tumors. We
previously identified tumor necrosis factor superfamily 15 (TNFSF15), a blood vascu-
lar endothelium‐derived cytokine, in lymphatic endothelial cells, as a key molecular
modulator during lymphangiogenesis. However, the effect of TNFSF15 on tumor
lymphatic metastasis and the underlying molecular mechanisms remain unclear. We
report here that TNFSF15, which is known to inhibit primary tumor growth by sup-
pressing angiogenesis, can promote lymphatic metastasis through facilitating lym-
phangiogenesis in tumors. Mice bearing tumors induced by A549 cells stably
overexpressing TNFSF15 exhibited a significant increase in densities of lymphatic
vessels and a marked enhancement of A549 tumor cells in newly formed lymphatic
vessels in the primary tumors as well as in lymph nodes. Treatment of A549 cells
with TNFSF15 results in upregulation of VEGFC expression, which can be inhibited
by siRNA gene silencing of death domain‐containing receptor‐3 (DR3), a cell surface
receptor for TNFSF15. In addition, TNFSF15/DR3 signaling pathways in A549 cells
include activation of NF‐κB during tumor lymphangiogenesis. Our data indicate that
TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor
lymphangiogenesis by upregulating VEGFC expression in A549 cells, contributing to
lymphatic metastasis in tumor‐bearing mice. This finding also suggests that TNFSF15
may have potential as an indicator for prognosis evaluation.
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1 | INTRODUCTION
Metastasis is the major cause of death in cancer patients, including
lung cancer,1,2 and the spread of tumor cells to lymph nodes has
been the main negative prognostic factor for lung cancer.3,4 Lym-
phatic metastasis is considered a major route for cancer cell dissemi-
nation,4,5 and the spreading of tumor cells to lymph nodes is a
common lymphatic‐mediated metastasis pattern for carcinomas,
draining either through preexisting lymphatic vessels or via the
newly formed lymphatic capillaries.6,7 However, the pathobiology for
lymphatic metastasis has remained unclear. Recent studies have
shown that some tumors secrete lymphangiogenic growth factors,
including vascular endothelial growth factor‐C (VEGFC) and vascular
endothelial growth factor‐D (VEGFD), which act on the lymphatic
vasculature to facilitate metastasis.8-11 In addition, other molecules/
substances, such as sine oculis homeobox homolog 1 (SIX1)9 in
breast cancer, lipopolysaccharide (LPS)10 in colorectal cancer and
high‐mobility group box 1 protein (HMGB1)12 in colon cancer, can
all promote lymphatic metastasis by increasing VEGFC expression.
However, although VEGFC and VEGFD have been identified as the
main signal factors for driving lymphangiogenesis, the mechanism by
which VEGFC or VEGFD is regulated in lung cancer is not clear. Fur-
ther elucidation of the pathogenesis of lymphatic metastasis in lung
cancer would represent a critical step forward for improving thera-
peutic strategies.
The tumor necrosis factor superfamily member TNFSF15 (also
known as TL1A or VEGI), a cytokine produced predominantly by
blood endothelial cells (BEC) in established blood vessels, is a speci-
fic inhibitor of BEC proliferation, being able to arrest growth in qui-
escent BEC but also to induce apoptosis in proliferating BEC.13
TNFSF15 inhibits angiogenesis by down‐modulating VEGF receptor‐
1 activities in endothelia progenitor cells (EPC).14 It also inhibits dif-
ferentiation of Lin−‐Sca‐1+ EPC into BEC and incorporation of EPC
into tumor vasculature in murine models.15 TNFSF15 expression is
high in the early stages, while is absent or marginal in the late stages
in various cancers.16-18 Indicating its importance in angiogenesis and
cancer progression, systemic administration of TNFSF15 led to inhi-
bition of tumor angiogenesis and growth.19 Furthermore, using an
embryonic lymphangiogenesis model, we recently demonstrated that
TNFSF15 facilitated lymphangiogenesis through upregulation of
VEGFR3 in lymphatic endothelial cells (LEC) in physiological condi-
tions.20 These studies suggested that TNFSF15 may participate in
tumor metastasis in the early stages by prompting tumor lymphan-
giogenesis. However, whether TNFSF15 is involved in tumor lym-
phangiogenesis and tumor metastasis in lung cancer remains to be
determined.
Therefore, in this study, we investigated the role of TNFSF15 in
tumor metastasis, particularly in lymphangiogenesis and lymphatic
metastasis, and attempted to explain the molecular mechanism of
TNFSF15 in regulating VEGFC expression in lung cancer. We report
here that TNFSF15 facilitates lymphatic metastasis in a mouse model
of lung cancer by upregulating VEGFC expression in A549 human
lung cancer cells and that this activity is mediated by death receptor
3 (DR3, also known as tumor necrosis factor receptor superfamily
member 25 or TNFRSF25) and nuclear factor (NF)‐κB signaling. Our
findings reveal a causal role for TNFSF15‐mediated lymphangiogene-
sis in tumors, which promotes lymphatic metastasis. We show that it
promotes lymphatic metastasis of lung cancer through upregulation
of lymphangiogenic growth factor VEGFC in cancer cells in a mouse
model of lung cancer.
2 | MATERIALS AND METHODS
2.1 | Animals and the subcutaneous lung cancer
model
Female nude mice (BALB/c‐nu, 6 weeks) were purchased from the
Model Animal Center of Nanjing University and housed in a patho-
gen‐free animal facility with ad libitum access to water and food. All
experimental procedures were performed in accordance with proto-
cols approved by the Institutional Animal Care and Research Advi-
sory Committee of Tianjin Medical University (Tianjin, China). To
induce a subcutaneous lung cancer model, nude mice were random-
ized into 2 groups (n = 5), and A549Control/EGFP or A549TNFSF15/EGFP
lung cancer cells (see below) were inoculated (5 × 106 cells per
mouse) in the subcutaneous space near the axillary lymph node of
nude mice, respectively. The animals were observed and weighted
every other day for 72 days. Tumor sizes were measured with a dial
caliper in a blinded manner. Tumor volumes were determined using
the equation: volume = width × width × length × 0.52. Metastases
were imaged with an IVIS Spectrum Imaging System (Caliper Life
Science, Hopkinton, MA, USA), by which A549Control/EGFP and
A549TNFSF15/EGFP tumors could be clearly visualized. Although auto‐
fluorescent signals were given by naïve animals, the high intensity of
fluorescent signal from A549Control/EGFP and A549TNFSF15/EGFP
tumors was distinguishable and can be normalized with background
signal. The mice were killed at the end of the experiment. The pri-
mary tumors and inguinal lymph nodes were retrieved for pathologic
analyses as described.21
2.2 | Cell culture and transfection
Human lung cancer cell line A549 was purchased from the American
Type Culture Collection (Manassas, VA, USA). A549Control/EGFP and
A549TNFSF15/EGFP cells were generated in our laboratory from A549
cells (see Supplementary Figure S1). In brief, the EGFP‐expressing
lentivector (Control/EGFP) and lentivector‐encoding TNFSF15
(TNFSF15/EGFP) were purchased from Genechem (Shanghai, China).
Prior to transfection, A549 cells were seeded in 6‐well plates
(1 × 105 cells per well), incubated overnight, then transduced with
lentiviral supernatants containing different lentiviral vectors, and
5 μg/mL polybrene in a humidified incubator at 37°C with 5% CO2
for 16 hours. Culture media were then removed and replaced with
fresh RPMI1640 medium (Gibco, Waltham, MA, USA) containing
10% FBS (Gibco), and cells were incubated for 72 hours. In addition,
primary LEC were isolated from the hyperplastic lymphatic vessels
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induced by Freund's incomplete adjuvant as described previously.22
LEC were cultured in ECM (ScienCell Laboratories, Carlsbad, CA,
USA) supplemented with endothelial cell growth supplement (Scien-
Cell Laboratories), 10% FBS, 100 μg/mL heparin, and 100 μg/mL
streptomycin and penicillin.
2.3 | Reagents
Antibodies for CD31, VEGFA, VEGFR3, podoplanin, Ki67 (ab92742,
an anti‐human Ki67 antibody that does not cross‐react with the
mouse Ki67), NF‐κB subunit p65 and VEGFC were purchased from
Abcam (Cambridge, London, UK). HRP‐conjugated secondary anti-
bodies were obtained from Cell Signaling Technology (Danvers, MA,
USA). Alexa Fluor 555‐conjugated secondary antibody was from
Invitrogen (Carlsbad, CA, USA). Pyrrolidine dithiocarbamate (PDTC,
an effective NF‐κB inhibitor) was purchased from Sigma‐Aldrich (St
Louis, MO, USA). A human VEGFC ELISA Kit was purchased from
R&D Systems (Minneapolis, MN, USA). TNFSF15 protein was kindly
given by Professor Lu‐yuan Li (Nankai University, Tianjin, China),
which was prepared as previously described.19
2.4 | Immunohistochemistry and
immunofluorescence assay
Five‐micrometer sections of formalin‐fixed, paraffin‐embedded
tumors and lymph nodes were deparaffinized and rehydrated and
then rinsed with PBS. For antigen retrieval, sections were micro-
waved in citric acid solution (PH 6.0) for 15 minutes. Then, these
slides were incubated in 3% H2O2 for 15 minutes. Sections were
incubated with antibodies against CD31, VEGFA, podoplanin, VEGFC
or Ki67 (ab92742, see Subsection 2.3) and then with appropriate sec-
ondary antibodies at room temperature (RT) for 30 minutes. Three
clinical pathologists assessed the intensity of the immunostaining on
each section independently and in a blinded manner, using a semi-
quantitative scoring system (0, 1, 2 and 3 for negative, weak, strong
and very strong, respectively). At least 10 fields per specimen were
surveyed. For immunofluorescent staining, fluorescein‐labeled anti-
body, including Alexafluor‐555 (red) anti‐human VEGFC and DAPI
from BioLegend (San Diego, CA, USA), was used. The slides were
incubated at RT for 1 hour in darkness. Immunostained sections were
imaged with a positive fluorescence microscope (Carl Zeiss, Oberko-
chen, Germany). A minimum of 10 fields per section was analyzed.
2.5 | Western blotting analyses
Total protein was extracted from homogenized cells in RIPA buffer
and subjected to 10% SDS‐PAGE. The proteins were transferred
onto polyvinylidenedifluoride membranes (Roche Molecular Bio-
chemicals, Quebec, Canada), blocked with 5% nonfat skimmed milk,
and then immunoblotted overnight at 4°C with appropriate primary
antibodies. The blots were further incubated with HRP‐conjugated
secondary antibodies and developed with the ECL System (Millipore,
Billerica, MA, USA).
2.6 | Quantitative RT‐PCR gene expression
analyses
Samples were collected and homogenized in TRIzol (Invitrogen). RNA
extraction and reverse transcription were performed following stan-
dard procedures. For PCR amplification of the cDNA fragment cod-
ing for targeted genes, the sense and antisense primer sequences for
human VEGFC,23 TNFSF15, p6524 and GAPDH were as follows,
respectively: 5′‐AGT GTC AGG CAG CGA ACA AGA‐3′ and 5′‐CTT
CCT GAG CCA GGC ATC TG‐3′; 5′‐TAG AGC CGA CGG AGA TAA
GCC‐3′ and 5′‐CCC ACG GAA TGT GAC CTG‐3′; 5′‐CCC CAC GAG
CTT G‐3′ and 5′‐CCA GGT TCT GGA AAC TGT GGA T‐3′; 5′‐ TGA
CTT CAA CAG CGA CAC CCA ‐3′ and 5′‐CAC CCT GTT GCT GTA
GCC AAA‐3′. The mRNA relative expression levels were calculated
after being normalized to that of internal control GAPDH.
2.7 | Vascular endothelial growth factor‐C ELISA
Samples of conditioned media from cells with (and without)
TNFSF15 treatment were collected. Levels of VEGFC were deter-
mined using the human VEGFC ELISA Kit (R&D Systems). The absor-
bance was measured with an Epoch microplate reader (BioTek,
Winooski, VT, USA).
2.8 | RNA interference
The siRNA for DR3 and NF‐κB subunit p65 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Scrambled siRNA
was purchased from GenePharma (Shanghai, China). The sense and
antisense sequences of scramble siRNA are as follows: 5′‐UUC UCC
GAA CGU GUC ACG UTT ‐3′ and 5′‐ACG UGA CAC GUU CGG
AGA ATT‐3′. Cells were transfected with siRNA using Lipofectamine
2000 Reagent (Invitrogen) according to the manufacturer's protocol,
and protein levels of the target gene products were determined by
western blot analyses of extracts made 72 hours later.
2.9 | Cell proliferation and migration assays
Lymphatic endothelial cells were activated with A549 cell‐condi-
tioned media (CM) (shControl and shVEGFC). To prepare CMs, A549
stable cell lines, transfected with lentivirus containing shControl or
shVEGFC, treated with (or without) TNFSF15, were cultured for
72 hours to produce shControl and Vehicle CM, shControl and
TNFSF15 CM, shVEGFC and Vehicle CM, and shVEGFC and
TNFSF15 CM. To determine the effects of CM treatment on LEC
proliferation, LEC cells were seeded (1 × 104 cells per well). Then,
shControl and Vehicle CM, shControl and TNFSF15 CM, shVEGFC
and Vehicle CM, and shVEGFC and TNFSF15 CM were added at
12 hours after seeding. Following 72‐hours incubation, cells were
trypsinized and counted. For migration assay, 8‐μm‐pore transwells
were used (Corning, Corning, NY); 5 × 104 LEC were seeded in the
transwell inserts pre‐equilibrated with media; shControl and Vehicle
CM, shControl and TNFSF15 CM, shVEGFC and Vehicle CM, and
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shVEGFC and TNFSF15 CM were added to the media in the lower
chambers. After 24‐hour incubation, the inserts were rinsed, fixed in
2% paraformaldehyde for 10 minutes, and then stained with crystal
violet (Beyotime, Haimen, Jiangsu, China). The numbers of cells that
migrated per field were counted on 6 randomly chosen fields per well
acquired at 200× magnification (ECLIPSE Ti, Nikon, Tokyo, Japan).
2.10 | Statistical analysis
The data were subjected to variance analysis (ANOVA), followed by
2‐tailed, unpaired Student's t test. Differences with P‐values <.05
were considered statistically significant.
3 | RESULTS
3.1 | Tumor necrosis factor superfamily 15 inhibits
primary tumor growth but promotes tumor
metastasis
To evaluate the influence of TNFSF15 in lymphatic metastasis
in vivo, human A549TNFSF15/EGFP cell line, which stably expresses
TNFSF15 or control cell line A549Control/EGFP (without TNFSF15
transfection) was implanted on the flanks of nude mice to establish
a mouse subcutaneous model of human cancer. A substantial inhibi-
tion in growth of primary tumors was observed in the A549TNFSF15/
EGFP group (Figure 1A) (n = 5). The median tumor volume in the
A549Control/EGFP group was more than 2 times that of the
A549TNFSF15/EGFP group (Figure 1B). Numerous metastases were
detected by stereomicroscopic imaging, which exhibited an increase
from approximately 3 on average per A549Control/EGFP mouse to 9
on average per A549TNFSF15/EGFP mouse (Figure 1C,D). Lower sur-
vival rate was detected (see Supplementary Figure S2). Furthermore,
we calculated the tumor sizes every other day for 72 days. The
A549TNFSF15/EGFP group showed a remarkable inhibition in primary
tumor growth (Figure 1E). These findings indicate that TNFSF15
plays opposite roles in primary tumor growth and tumor metastasis;
namely, TNFSF15 can promote tumor metastasis but inhibit tumor
growth.
3.2 | Tumor necrosis factor superfamily 15
upregulates vascular endothelial growth factor‐C
while downregulates vascular endothelial growth
factor‐A in primary tumors
To determine the effect of TNFSF15 on blood and lymphatic vessel
densities, CD31 and podoplanin expression was examined. We car-
ried out immunohistochemical staining of the CD31, podoplanin,
VEGFA and VEGFC proteins in primary tumors of these 2 groups,
and found that the expression patterns of CD31 and VEGFA, which
are related to angiogenesis, are strikingly different to patterns of
F IGURE 1 Tumor necrosis factor
superfamily 15 (TNFSF15) enhances tumor
metastasis while it inhibits primary tumor
development. A, Typical images of the
primary tumors that formed in mice
grafted with A549Control/EGFP or
A549TNFSF15/EGFP tumor cells on the right
shoulder. Ruler unit: cm. B, Box plots of
volumes of primary tumors (n = 5 per
group). C, Representative images of mice
with tumor cells grafted to promote
spontaneous metastasis, which can be
monitored using the IVIS spectrum imaging
system. Color bar represents radiant
efficiency ([p/s/cm2/sr]/[μW/cm2]). D, A
scatter plot analysis of metastases showing
a more than 2.5 times incensement in the
A549TNFSF15/EGFP when compared to the
A549Control/EGFP control group. E, The
effect of TNFSF15 on tumor growth.
These experiments were repeated 2 times.
Data are mean ± SD. ***P < .001;
Student's t test
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podoplanin and VEGFC. We found that CD31 and VEGFA proteins
were downregulated markedly in the TNFSF15 group when com-
pared to the control group, and that, in sharp contrast, the TNFSF15
group showed higher podoplanin and VEGFC levels (Figure 2A).
Blood vessel densities (CD31+) on cross‐sections of the primary
tumors in the control group were more than 3 times those of the
TNFSF15 group (Figure 2B). We determined VEGFA and VEGFC
protein levels using a 4‐step grading system (0, 1, 2 and 3 for nega-
tive, weak, strong and very strong staining, respectively). While
VEGFA expression was high or very high in the control group, it was
negative or low in the TNFSF15 group (Figure 2C). We obtained the
opposite results for VEGFC expression (Figure 2D). Lymphatic vessel
densities (podoplanin+) were significantly higher in the TNFSF15
group than those in the control group, with the median values being
3 and 9 per field, respectively (Figure 2E). These findings indicate
that TNFSF15 plays inverse roles in tumor angiogenesis and tumor
lymphangiogenesis.
3.3 | Tumor necrosis factor superfamily 15
promotes lymphatic metastasis
Because tumor lymphangiogenesis provides an important route for
lymphatic metastasis, we next determined whether the upregulation
of VEGFR3 podoplanin and VEGFC under TNFSF15 can promote
tumor lymph node metastasis. Autopsy analysis showed that most of
the tumor‐bearing mice in the TNFSF15 group developed metastatic
lesions in inguinal lymph nodes, which were also much larger in vol-
umes when compared to the control group (Figure 3A,C). Ki67,
which is a proliferation marker, is used to present metastasis of
human tumor cells as the anti‐human Ki67 (ab92742) antibody does
not cross‐react with mouse Ki67.21 Ki67 staining of lymph nodes
confirmed the metastatic lesions (Figure 3B), and analysis of primary
tumor metastasis to inguinal lymph nodes (which was quantified by
the number of human Ki67‐positive cells per unit area) showed more
than 3 times in the TNFSF15 group than that in control group
F IGURE 2 Role of tumor necrosis
factor superfamily 15 (TNFSF15) in
modulating podoplanin, vascular
endothelial growth factor‐C (VEGFC),
CD31 and VEGFA expression. A, Typical
images (brown) of VEGFA and CD31
immunostaining of blood vessels, and
representative images of VEGFC and
podoplanin immunostaining of lymphatic
vessels in primary tumors in mice grafted
with A549Control/EGFP or A549TNFSF15/EGFP
tumor cells. Magnification, ×200, scale bar:
50 μm, pictures in lines 1 and 3;
magnification, ×400, scale bar: 50 μm,
pictures in lines 2 and 4. B, Average blood
vessel density as quantified by assessing
the numbers of CD31‐positively stained
vessels in primary tumors of mice (n = 5
per group). C, VEGFA expression as
quantified using a semiquantitative scoring
system as described in the Materials and
Methods. D, Average lymphatic vessel
density as quantified by assessing the
numbers of podoplanin‐positively stained
vessels in primary tumors of mice (n = 5
per group). E, VEGFA expression as
quantified using a semiquantitative scoring
system as described. Data are mean ± SD
(n = 5). **P < .01, ***<.001 Student's
t test. These experiments were performed
2 times
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(Figure 3D). Collectively, these results provide compelling evidence
that TNFSF15 is a positive regulator of lymphatic metastasis.
3.4 | Tumor necrosis factor superfamily 15
upregulates vascular endothelial growth factor‐C
expression in A549 lung cancer cells
We treated A549 cells with recombinant TNFSF15 (200 ng/mL, a con-
centration which was used previously to treat lymphatic endothelial
cells)20 and found that the treatment resulted in a considerable
increase in VEGFC protein levels as determined by immunofluores-
cent staining (Figure 4A). Fluorescence intensity assessment revealed
that VEGFC protein levels in TNFSF15‐treated group were 4 times of
that in vehicle‐treated group (Figure 4B). In addition, we treated A549
cells with recombinant TNFSF15 (200 ng/mL) for 24 hours and found
that the treatment resulted in a considerable increase in VEGFC pro-
tein levels as determined by western blotting analyses (Figure 4C).
We also found that DR3, the receptor that mediates TNFSF15 activi-
ties in ECs, was expressed in a high but constant level in A549 cells
under the experimental conditions (Figure 4C). The increase in VEGFC
level became apparent within 12 hours of TNFSF15 (200 ng/mL)
treatment, reaching a level more than 2 times than that in vehicle‐
treated cells within 24 hours (Figure 4D). Real‐time PCR analyses
revealed that TNFSF15 (200 ng/mL) treatment gave rise to a more
than 2‐fold increase in VEGFC mRNA within 3 hours (Figure 4E). Fur-
thermore, we determined VEGFC concentration in the medium by
ELISA and found that VEGFC levels under the TNFSF15 treatment
were more than 4 times those in the vehicle‐treated group (Figure 4F).
These data indicate that TNFSF15, which is predominantly expressed
by vascular endothelial cells, is able to substantially stimulate VEGFC
gene expression in A549 lung cancer cells.
3.5 | DR3/NF‐κB signaling pathway is involved in
tumor necrosis factor superfamily 15‐stimulated
vascular endothelial growth factor‐C production in
A549 cells
To determine whether DR3 mediates upregulation of VEGFC in
A549 cells, we treated A549 cells with scrambled or DR3 siRNA
(40 pmol/mL, respectively) to silence the gene of DR3 and then trea-
ted with (or without) TNFSF15 (200 ng/mL). The DR3 siRNA treat-
ment resulted in a >90% decline in DR3 protein levels, rendering a
diminished ability of TNFSF15 to induce VEGFC protein expression
(Figure 5A). Secretion of VEGFC is partly promoted by the NF‐κB
signaling pathway.25 To find out whether this signaling pathway is
involved in TNFSF15‐stimulated VEGFC secretion by A549 cells, we
treated the cells with PDTC (0.25 μmol/L), a known NF‐κB inhibitor.
PDTC treatment led to an apparent reduction in TNFSF15‐induced
F IGURE 3 Relationship between tumor
necrosis factor superfamily 15 (TNFSF15)
and volumes of inguinal lymph nodes and
Ki67 expression. A, Images of inguinal
lymph nodes dissected from different
groups of mice. Ruler unit: cm. B, Typical
images of A549 cells positively stained
(brown) for human Ki67. Magnification,
×400, scale bar: 50 μm. C, Average
volumes of inguinal lymph nodes. D,
Number of Ki67‐positive A549 cells. Data
are mean ± SD (n = 5 per group).
**P < .01, ***P < .001, Student's t test.
These experiments were performed 2
times
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VEGFC upregulation at both mRNA and protein levels (Figure 5B,C).
Furthermore, prior treatment of A549 cells with siRNA against
NF‐κB subunit p65 (40 pmol/mL), which effectively silenced p65
gene (Figure 5D), abolished the ability TNFSF15 to stimulate VEGFC
expression (Figure 5E,F,G,H). These findings indicate that NF‐κB sig-
naling is responsible for mediating TNFSF15‐mediated upregulation
of VEGFC gene expression in A549 cells.
3.6 | Tumor necrosis factor superfamily 15
facilitates vascular endothelial growth factor‐C‐
stimulated lymphatic endothelial cell migration and
proliferation
We determined the impact of VEGFC upregulated by TNFSF15 on
the ability of LEC to migrate and proliferate. First, we constructed a
VEGFC knockdown stable cell line with VEGFC shRNA in A549 lung
cancer cells, in which the VEGFC silencing effect was clearly identi-
fied (Figure 6A). Using a transwell migration assay, which measures
the number of LEC that pass across a filter under the experimental
conditions (Figure 6B), we found that treatment with conditioned
medium of TNFSF15 (200 ng/mL)‐treated A549 cells led to more
than a doubling of the migration ability of the LEC when compared
to that from vehicle‐treated cells and that this effect can be blocked
by VEGFC silencing (Figure 6C). Furthermore, to determine whether
VEGFC upregulated by TNFSF15 can promote LEC proliferation, we
treated LEC with conditioned media from A549 shControl or A549
shVEGFC cell cultures for 72 hours, and the cell numbers were
counted. We found that TNFSF15‐treated cell medium led to a 1.5‐
fold enhancement of the proliferation rate of LEC and that this
effect can also be blocked by VEGFC silencing (Figure 6D).
4 | DISCUSSION
Tumor necrosis factor superfamily 15, a cytokine secreted by
endothelial cells, has important effects on anti‐angiogenesis and pro‐
lymphangiogenesis. Previous studies have found that TNFSF15 can
inhibit tumor growth via anti‐angiogenesis.17,19,26 In addition, the
effect of TNFSF15 on lymphangiogenesis had also been studied
under physiological conditions.20 However, the role of TNFSF15 in
tumor metastasis and the underlying mechanism remain unknown.
Here, we have demonstrated that TNFSF15 can stimulate VEGFC
gene expression in A549 lung cancer cells and that VEGFC secreted
from A549 cells can promote lymphatic endothelial cell (LEC) prolif-
eration and migration, and stimulate tumor lymphangiogenesis and
lymphatic metastasis. Furthermore, mechanistically, we observed that
DR3, the cell surface receptor of TNFSF15, mediates the upregula-
tion of VEGFC expression by activating the NF‐κB signaling
F IGURE 4 Tumor necrosis factor
superfamily 15 (TNFSF15) upregulates
vascular endothelial growth factor‐C
(VEGFC) expression in A549 tumor cells. A,
Fluorescence microscopy images of A549
cells treated with vehicle or TNFSF15 for
24 h. Red, VEGFC; blue, DAPI;
magnification, ×400, scale bar: 20 μm. B,
Analyses of fluorescence intensities of
VEGFC+ cells. C, Western blot analyses
showing VEGFC and DR3 protein levels
following TNFSF15 treatment at various
concentrations. Values are normalized to β‐
actin. D, Western blot analyses showing
VEGFC levels in vehicle‐treated and
TNFSF15‐treated A549 cells at the
indicated time points. E, VEGFC mRNA
levels in treated A549 cells, as determined
by RT‐PCR. F, VEGFC concentrations in
the culture medium of A549 cells
untreated or treated with TNFSF15, as
determined by ELISA. Data are mean ± SD.
**P < .01; ***P < .001, Student's t test.
These experiments were performed 3
times
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pathway. Subsequently, DR3/NF‐κB signal activation results in
upregulation of VEGFC expression and facilitates VEGFC‐dependent
LEC proliferation, migration, and tumor lymphangiogenesis and lym-
phatic metastasis (Figure 7). Thus, our investigation has for the first
time revealed the effect of TNFSF15 on lymphatic metastasis in lung
cancer, which has shed light on the prevention and treatment of
lung cancer metastasis.
Tumor necrosis factor superfamily 15 can inhibit angiogenesis
and promote lymphangiogenesis in a mouse model of lung cancer.
Typically, both types of vessels grow or regress in parallel, which is
consistent with our previous notion. In brief, the TNFSF15/DR3 sig-
naling pathway may lead to different results, depending on the types
of cells in which it is activated, and it leads to apoptosis in VEC and
proliferation in LEC.20
Tumor cell metastasis to regional lymph nodes is an early event
in metastatic tumor spread and is frequently used as a prognostic
factor for disease outcome. The existence and functionality of intra-
tumoral lymphatics in human and experimental rodents remain con-
troversial. Our findings indicate that TNFSF15‐promoted
lymphangiogenesis via upregulation of VEGFC in A549 cells provides
portals for tumor metastasis, and the invasion of tumor cells into the
lymphatic vessels is a critical step in metastasis. Given that TNFSF15
protein levels are highly expressed in the early stages (FIGO stages I
and II) of cancer,18 it would be meaningful to explore the potential
correlation between TNFSF15 expression and occurrences of regio-
nal lymph node metastasis.
It has been affirmatively shown that DR3 works as the cell sur-
face receptor of TNFSF15 in blood vascular endothelial cells,27
F IGURE 5 DR3 mediates tumor
necrosis factor superfamily 15 (TNFSF15)‐
stimulated upregulation of vascular
endothelial growth factor‐C (VEGFC). A,
Changes in DR3 and VEGFC protein levels
following TNFSF15 treatment in the
presence or absence of DR3 siRNA
(40 pmol/mL). B, Changes in VEGFC mRNA
in response to TNFSF15 treatment in the
presence or absence of NF‐κB inhibitor
PDTC (1 μmol/L), as determined by RT‐
PCR. C, Western blot analyses showing
treatment effect of PDTC on TNFSF15‐
induced VEGFC upregulation. D, Changes
in p65 mRNA levels in the presence or
absence of p65 siRNA (40 pmol/mL). E,
Changes in VEGFC mRNA levels following
TNFSF15 treatment in the presence or
absence of p65 siRNA. F, Changes in p65
and VEGFC protein levels following
TNFSF15 treatment in the presence or
absence of p65 siRNA. G, Quantitative
analyses of p65 protein levels in the
presence or absence of p65 siRNA. H,
Quantitative analysis of VEGFC protein
levels following TNFSF15 treatment in the
presence or absence of p65 siRNA. Data
are mean ± SD. ***P < .001; one‐way
ANOVA. These experiments were repeated
3 times
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lymphatic endothelial cells,20 T cells28 and dentritic cells.29 Experi-
mental data for this study show that DR3 is the receptor of
TNFSF15 in A549 cells and that the DR3 siRNA treatment of A549
lung cancer cells results in a blockade of TNFSF15‐induced VEGFC
upregulation. Furthermore, our study shows that DR3 is involved in
mediating TNFSF15 activity in VEGFC upregulation through a mech-
anism involving the NF‐κB signaling pathway. Activation of NF‐κB
can be directly linked to VEGFC upregulation, because VEGFC
upregulation, which is induced by TNFSF15, can be inhibited when
treated with either NF‐κB inhibitor PDTC or NF‐κB subunit p65
siRNA in A549 cells. Our finding is consistent with previous studies
on ovarian or colon cancer that NF‐κB activation can induce the pro-
duction of VEGFC.10,12,30
In summary, this study indicates that cytokine TNFSF15 pro-
motes lymphatic metastasis of lung cancer via upregulation of lym-
phangiogenic growth factor VEGFC in A549 lung cancer cells in a
mouse model of lung cancer. Mechanistically, this activity is medi-
ated by DR3 and subsequent activation of the NF‐κB signaling path-
way in A549 cells. Further delineation of this signaling pathway
could lead to insights into the molecular mechanisms underlying
tumor lymphangiogenesis, modulation of lymphatic metastasis and
new targets for clinical intervention in lymphatic metastasis.
F IGURE 6 Tumor necrosis factor
superfamily 15 (TNFSF15) facilitates
vascular endothelial growth factor‐C
(VEGFC)‐stimulated lymphatic endothelial
cell (LEC) migration and proliferation. A,
Changes in VEGFC protein levels following
TNFSF15 treatment in the presence or
absence of VEGFC shRNA. B, Typical
immunostaining images of migrated LEC in
transwell migration assays following
conditioned media treatment. Blue, LEC.
Magnification, ×5, scale bar: 100 μm. C,
Changes in numbers of migrated cells. D,
The relative numbers of cells following
treatment with A549 tumor cell‐
conditioned media. Data are mean ± SD.
***P < .001; one‐way ANOVA. These
experiments were repeated 3 times
F IGURE 7 A schematic presentation of
process involved in the lymphatic
metastasis promoted by tumor necrosis
factor superfamily 15 (TNFSF15). TNFSF15
binds to its receptor DR3 on A549 lung
tumor cells, which subsequently causes
activation of the NF‐κB signaling pathway
and secretion of vascular endothelial
growth factor‐C (VEGFC) by the A549
cells. VEGFC then promotes
lymphangiogenesis and, consequently,
lymphatic metastasis via the newly formed
lymphatic vessels in primary tumors
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